Published in Cancer Weekly, July 6th, 2004
This randomized trial demonstrated that the addition of Eloxatin to gemcitabine, the current standard chemotherapy for pancreatic cancer, achieved significantly better results than gemcitabine alone in terms of response rate, progression-free survival, and clinical benefit response.
"The results of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.